Two small defense-tech companies, both riding the same macro tailwind (U.S. military modernization, counter-UAS, space proliferation), but attacking it from completely different angles. Frequency Electronics makes the timing heartbeat — ultra-precise atomic clocks that keep satellites, missiles, and…
Two small defense-tech companies, both riding the same macro tailwind (U.S. military modernization, counter-UAS, space proliferation), but attacking it from completely different angles. Frequency Electronics makes the timing heartbeat — ultra-precise atomic clocks that keep satellites, missiles, and encrypted radios synchronized. nLIGHT makes the lasers that shoot down drones. Same buyer (Pentagon), same geopolitical urgency, radically different business profiles, risk characteristics, and valuations.
| Metric | FEIM | LASR |
|---|---|---|
| Company Name | Frequency Electronics, Inc. | nLIGHT, Inc. |
| Sector / Industry | Technology / Communication Equipment | Industrials / Electrical Equipment |
| Market Cap | $397M | $3,670M |
| Enterprise Value | $405M | $3,570M |
| Price | ~$40.38 | ~$65.76 |
| 52-Week Range | $14.41 – $61.47 | $6.20 – $72.90 |
| 52-Week Performance | +155% | ~+960% |
| Distance from 52-Week High | -34.3% | -9.8% |
| Dividend Yield | 0% (special dividends only) | 0% |
| Beta | 0.31 | 2.34 |
The size difference is striking — LASR is 9x the market cap of FEIM. But LASR’s revenue is only 3.7x FEIM’s. The gap is almost entirely the market’s premium for LASR’s directed energy growth story. FEIM’s low beta (0.31) makes it a defensive defense stock, while LASR’s 2.34 beta means it moves like a speculative growth name.
FEIM has been making precision timing products since 1961. Think of their products as the metronome inside every critical military and space system — crystal oscillators, oven-controlled oscillators (OCXOs), rubidium atomic clocks, hydrogen masers, and secure GPS receivers. Without precise timing, encrypted communications can’t synchronize, satellites drift out of position, and missile guidance fails. FEIM’s products are the smallest, cheapest component in a satellite or weapons system, but they’re the one that makes everything else work. It’s a 226-person company on Long Island that has put timing products on 120+ space programs over 63 years.
LASR is a vertically integrated high-power laser company that has pivoted from a commoditizing industrial business into defense directed energy. They make the semiconductor pump diodes, specialty optical fiber (LIEKKI brand, Finland), fiber lasers (Corona AFX for 3D printing), and complete directed energy weapon systems including beam combining and adaptive optics (Nutronics acquisition). The big story is HELSI — a $171M contract to develop a megawatt-class laser weapon for the Army — and DE M-SHORAD, a $34.5M contract for 50kW counter-drone lasers on Stryker vehicles.
| Dimension | FEIM | LASR |
|---|---|---|
| Revenue Model | Fixed-price & cost-plus government contracts, product sales | Product sales + government R&D contracts |
| Revenue Segments | Satellite payloads (59%), Non-space DoD (38%), Commercial (3%) | A&D (~67%), Industrial/Commercial (~33%) |
| Geographic Mix | ~94% U.S. | Predominantly U.S. (defense); some international industrial |
| Customer Concentration | Very High — 94% U.S. government | High — DoD likely 50%+ |
| Competitive Moat | Switching costs + heritage (Strong) | IP/patents + vertical integration (Strong for defense) |
| TAM & Penetration | Precision timing for space/defense: ~$2-3B, small share | Directed energy weapons: $5-10B+ by 2030, early share |
| Secular Tailwinds | Proliferated satellites, Golden Dome, GPS-denied warfare, quantum sensing | Counter-UAS, directed energy weapons, additive manufacturing |
FEIM has the more durable business model. Precision timing is deeply embedded, mission-critical, and essentially impossible to rip out and replace — 63 years of flight heritage data creates switching costs that no competitor can replicate. The product is small and cheap relative to the total system cost, which means pricing power and budget resilience. Nobody is going to cancel a $500M satellite to save $200K on oscillators.
LASR has the larger runway for growth. The directed energy weapons market is in its infancy and could be worth $5-10B+ by 2030. If LASR’s fiber-based architecture wins the production competition (vs. Lockheed Martin’s slab approach), the revenue potential is multiples of today’s $261M. But this is a bigger, riskier bet.
Business model red flags: LASR has never posted a profitable year in 25 years of operation, with SBC running 11-14% of revenue annually and 69% share dilution since IPO. FEIM had a one-time $11.9M tax benefit in FY2025 that inflated reported earnings — normalize for that and the profitability picture is more modest. FEIM’s cash also dropped to $86K at the January quarter-end, though management said $11M+ was collected shortly after.
| Metric | FEIM | LASR |
|---|---|---|
| Revenue (LTM) | $67.8M | $261.3M |
| Revenue Growth (YoY, latest FY) | +26.3% | +31.6% |
| Revenue Growth (3Y CAGR) | ~13% | ~-1% (revenue declined FY21-FY24 before rebounding) |
| Revenue Growth (NTM est.) | Revenue estimates revised down ~15% | ~+9% (~$285M consensus) |
| Gross Margin | 37.9% (LTM) | 29.8% (FY25) |
| Operating Margin | 9.8% (LTM) | -10.2% (FY25) |
| Net Margin | 10.6% (LTM) | -9.0% (FY25) |
| EPS (TTM) | $0.73 | -$0.47 |
| EPS Growth (YoY) | Volatile (tax benefit distortion) | Improving (from -$1.27 to -$0.47) |
| EPS (NTM est.) | ~$1.18-1.32 | ~$0.30 |
| Metric | FEIM | LASR |
|---|---|---|
| FCF (LTM) | -$3.8M | $12.3M |
| FCF Margin | -5.6% | 4.7% |
| FCF Yield | N/M (negative FCF) | ~0.3% |
| Net Debt (Cash) | $8.0M net debt | -$97.4M (net cash) |
| Net Debt / EBITDA | 0.75x | N/M (net cash) |
| Current Ratio | 2.60x | 3.78x |
| Cash & Equivalents | $0.09M (Jan ’26; $11M+ collected post-quarter) | $133.6M |
LASR is financially healthier right now, which is counterintuitive for a money-losing company. The $201M equity offering in February 2026 loaded the balance sheet with $133.6M in cash and zero meaningful debt. LASR also just turned FCF positive ($12.3M in FY2025), which is the first time in recent memory.
FEIM is profitable on a GAAP basis but the cash position is precarious — $86K at the January quarter-end is alarming for a company with $67.8M in revenue. Management says this is a timing issue (large AR collections came in February), and the working capital position ($32M) is fine, but it’s a yellow flag. FEIM is also FCF negative in the LTM period despite GAAP profitability, driven by inventory buildup ($25.8M, up from $23.5M) as they ramp for satellite production.
Ranking: LASR > FEIM on balance sheet strength. FEIM > LASR on profitability and earnings quality (FEIM actually makes money; LASR doesn’t, on a GAAP basis).
| Metric | FEIM | LASR |
|---|---|---|
| Revenue CAGR (3Y historical) | ~13% | ~-1% (declining then rebounding) |
| Revenue CAGR (3Y forward est.) | ~10-15% (backlog-driven, limited analyst estimates) | ~15-20% (defense ramp, analyst consensus) |
| EPS CAGR (3Y historical) | N/M (went from loss to profit) | N/M (still in losses) |
| EPS CAGR (3Y forward est.) | ~15-20% (from ~$1.25 base, limited visibility) | N/M (from negative to barely positive) |
| FCF CAGR (3Y historical) | Volatile (positive to negative) | Improving (negative to $12.3M) |
| R&D as % of Revenue | 8.7% | 18.4% |
| Backlog | $83M (all-time record, heading to $100M+) | Not disclosed; HELSI $171M + DE M-SHORAD $34.5M contracted |
| M&A Activity | None recent | Nutronics ($33M, 2019), plasmo (2022) |
FEIM: 1. Proliferated satellite contracts ($45M just announced): Two large satellite awards in March 2026, with management expecting awards of “similar magnitude” later in calendar 2026. This is the biggest near-term catalyst. 2. TURbO miniaturized atomic clock: ~$20M annual market opportunity starting FY2027 for drone fleet timing and airborne radars. This is a new product ramping into production. 3. Golden Dome / missile defense timing components: Bipartisan political support for missile defense means sustained demand for FEIM’s precision timing in interceptor and sensor systems.
LASR: 1. HELSI Phase 2 milestones: Scaling from 300kW demonstrated to megawatt-class. Any successful demonstration is a major catalyst. 2. Defense production contract transition: The shift from development contracts ($171M HELSI, $34.5M DE M-SHORAD) to production contracts (potentially $500M-1B+ per year) would be transformational. 3. EOS partnership commercialization: Corona AFX lasers in next-gen EOS metal 3D printers starting commercial shipments.
Current momentum: Roughly equal. FEIM grew revenue 26% in FY2025 and has an $83M record backlog. LASR grew 31.6% in FY2025 with accelerating defense revenue. Both are in strong revenue growth phases.
Forward runway: LASR >> FEIM. The directed energy TAM ($5-10B+ by 2030) dwarfs the precision timing market (~$2-3B). If LASR wins defense production contracts, the upside is measured in multiples of current revenue. FEIM’s growth, while real, is more incremental — from $70M to perhaps $100-120M over the next 3 years. Both are exciting growth stories for their respective sizes, but LASR’s potential outcome is an order of magnitude larger.
| Multiple | FEIM | LASR |
|---|---|---|
| P/E (TTM) | 55.2x | N/M (negative) |
| P/E (NTM) | ~34x | ~203x |
| EV/EBITDA (TTM) | 47.0x | ~152x |
| EV/Revenue (TTM) | 6.0x | 13.7x |
| EV/Revenue (NTM) | ~5.5x | ~12.5x |
| P/FCF | N/M (negative FCF) | ~298x |
| P/B | 6.6x | ~16.1x |
| PEG Ratio | 9.78x | N/M |
| Stock | NTM P/E | 5Y Avg P/E | Premium / Discount | Justified? |
|---|---|---|---|---|
| FEIM | ~34x | ~25-30x (est.; limited data) | +15-35% premium | Partially — backlog growth justifies some re-rating, but FCF negative is a concern |
| LASR | ~203x | N/M (rarely profitable) | N/M | Stock is at the highest EV/Revenue in its history (14x vs. historical 1-6x) |
| Stock | NTM P/E | EPS Growth (NTM) | PEG | Verdict |
|---|---|---|---|---|
| FEIM | ~34x | ~60-80% (from $0.73 to $1.25+) | ~0.4-0.6x | Reasonable on PEG (but growth is partly tax normalization, not organic) |
| LASR | ~203x | N/M (from loss to $0.30) | N/M | Expensive by any earnings-based metric; only makes sense on revenue multiples |
FEIM is cheaper, but neither is a bargain.
FEIM at 6x EV/Revenue and 34x forward P/E is rich for a sub-$100M revenue defense components company with negative FCF and lumpy revenue recognition. But the $83M backlog and $45M in fresh contracts provide tangible support. The stock is also 34% off its highs, so some of the froth has already come out.
LASR at 13.7x EV/Revenue and 203x forward P/E is pricing in a massive future that hasn’t materialized yet. The only way to justify this valuation is if defense production contracts worth billions start flowing in the 2028-2030 timeframe and margins expand dramatically. Even bullish analysts have targets 23% below the current price.
On a growth-adjusted basis: FEIM > LASR (cheaper relative to near-term earnings growth). But LASR’s optionality on directed energy production contracts is genuinely unique — you can’t buy that option anywhere else in the public market.
| Metric | FEIM | LASR |
|---|---|---|
| ROIC | 10.0% | Negative |
| ROE | 12.9% (LTM) | Negative |
| ROIC vs. WACC | Creating value (modestly) | Destroying value |
| Insider Ownership | 6.25% | ~4.0% |
| Recent Insider Activity | Buying (4 buys, 0 sells in past year) | Selling ($20M+ sold, 0 bought) |
| Buyback Yield (TTM) | ~0.4% ($1.68M) | 0% (never executed authorized buyback) |
| Dividend Growth (3Y CAGR) | N/A (special dividends only) | N/A (no dividend) |
| Payout Ratio | N/A (special dividends) | N/A |
| Capital Allocation Grade | B | B+ |
FEIM: Conservative, shareholder-friendly for a micro-cap. Two $1.00/share special dividends ($9.3M and $9.6M). New $20M buyback authorized September 2025 (only $1.68M executed so far). No M&A — growth is entirely organic. The knock is that management has been slow to deploy the buyback even as the stock pulled back 34%. Capital allocation is competent but not aggressive.
LASR: The Nutronics acquisition ($33M in 2019) was a home run — it created the directed energy capability driving a $3.67B market cap. That single deal earns a high grade. But the $201M equity offering at $44 followed by insider selling at $60+ is optically poor. SBC at 11-14% of revenue is a chronic drag. The $10M buyback authorized in 2019 was never executed. Capital allocation is visionary on the strategic level but dilutive on the shareholder level.
FEIM >> LASR on quality. FEIM actually earns a positive ROIC, has insiders buying, pays dividends, and generates (usually) positive cash flow. LASR has never been sustainably profitable and insiders are selling. The quality gap is wide.
However, LASR’s quality deficit is partly by design — they’ve been investing heavily in directed energy capabilities that haven’t reached production scale yet. If they do, ROIC will flip positive and the quality picture will change dramatically. FEIM’s quality is proven; LASR’s is promised.
| Risk Dimension | FEIM | LASR |
|---|---|---|
| Cyclicality | Low (mission-critical, small cost item) | Moderate (defense budgets + industrial cycles) |
| Customer Concentration | Very High (94% U.S. government) | High (DoD likely 50%+) |
| Regulatory Risk | Low (ITAR compliance is a moat) | Low (ITAR is a moat) |
| Leverage Risk | Low (essentially debt-free) | Low (net cash) |
| Key-Person Risk | High (founder Martin Bloch, age ~93) | Moderate (founder-CEO Keeney, but team is deep) |
| Competitive Disruption Risk | Low (63 years of switching costs) | Moderate (Lockheed Martin architecture competition) |
| Macro Sensitivity | Low (beta 0.31) | High (beta 2.34) |
| Valuation Risk | Moderate (55x P/E but 34% off highs) | Very High (14x sales, 203x forward P/E, near all-time high) |
| Liquidity Risk | High (thin float, $86K cash at quarter-end) | Low ($133.6M cash, liquid stock) |
| Dilution Risk | Low (share count barely growing) | High (69% dilution since IPO, 4-5% annual SBC) |
FEIM — Key-person risk. Martin Bloch founded the company in 1961 and is now approximately 93 years old. He still serves as Executive Chairman and Chief Scientific Officer. His institutional knowledge — 63 years of physics, engineering, and customer relationships — is irreplaceable. When Bloch eventually steps away (or passes), the stock will face a sentiment shock regardless of whether the business is actually impaired. Dr. Tom McClelland (CEO, 40-year veteran) provides continuity, but the market will likely treat a Bloch departure as a material event.
LASR — Valuation and execution risk. At 14x sales and 203x forward P/E, the stock has essentially zero margin for error. If HELSI Phase 2 hits a technical wall, if the Army selects Lockheed Martin’s architecture for production, or if revenue growth slows to single digits, the stock could easily revisit $20-25 (where it was 6 months ago). The entire valuation is a bet on a future that hasn’t happened yet. Every quarterly earnings report is a pass/fail test at this multiple.
FEIM is lower risk overall. The beta of 0.31 tells you this — it barely moves with the broader market. The product is deeply embedded, mission-critical, and cheap relative to system cost. The risks are narrow and specific (Bloch succession, lumpy quarters). The valuation, while not cheap, has corrected 34% from highs.
LASR is significantly higher risk. Beta of 2.34, valuation at nosebleed levels, no GAAP profitability, insiders selling, and the entire thesis dependent on defense programs that are 2-4 years from production decisions. The upside is proportionally larger, but so is the downside.
| Technical Dimension | FEIM | LASR |
|---|---|---|
| Trend (50d vs. 200d MA) | Below 50-DMA ($51.84), above 200-DMA ($36.56) | Above both (strong uptrend) |
| RSI (14-day) | 34.2 — approaching oversold | Elevated (~60-65, neutral-to-overbought) |
| Distance from 52-Week High | -34.3% | -9.8% |
| Recent Volume Trend | Elevated selling volume | Elevated buying volume |
| Near-Term Setup | Favorable (pullback in uptrend, near oversold) | Unfavorable (extended, near highs, rising on momentum) |
FEIM offers the better entry timing right now. The stock has pulled back 34% from its January high of $61.47, is approaching oversold territory (RSI 34), and is still above its 200-day moving average ($36.56). The pullback was driven by revenue softness in Q3 FY2026 and general small-cap selling, not a fundamental deterioration — the $45M contract win and $83M record backlog came during the pullback. If the 200-DMA (~$36.56) holds as support, the risk/reward from ~$40 is attractive for a trade or a position build.
LASR should be watched, not chased. The stock is near all-time highs, has gone from $6 to $73 in a year, and even bullish analysts have targets below the current price. Entry here is chasing momentum. A pullback to the $45-50 range (closer to analyst consensus and the recent offering price of $44) would be a much better entry. The next natural entry point is the Q1 FY2026 earnings (May 7) — if results disappoint, you get a better price; if they impress, the stock likely gaps up and you pay more but with reduced risk.
| Dimension | Weight | FEIM | LASR |
|---|---|---|---|
| Business Quality | 20% | 4.0/5 | 3.5/5 |
| Financial Health | 15% | 3.0/5 | 3.5/5 |
| Growth | 20% | 3.5/5 | 4.5/5 |
| Valuation | 20% | 3.0/5 | 1.5/5 |
| Quality & Capital Allocation | 10% | 4.0/5 | 2.5/5 |
| Risk (inverted — higher score = lower risk) | 10% | 3.5/5 | 2.0/5 |
| Technical Timing | 5% | 4.0/5 | 2.0/5 |
| Weighted Score | 100% | 3.46 | 2.96 |
Score breakdown:
| Rank | Ticker | Weighted Score | Verdict | One-Line Rationale |
|---|---|---|---|---|
| 1 | FEIM | 3.46 | BUY | Record backlog, 34% pullback, proven profitability, near oversold — the risk/reward from $40 is attractive |
| 2 | LASR | 2.96 | WATCH | Exceptional technology positioning, but 14x sales with no GAAP profitability at near all-time highs is not the right entry |
Buy FEIM at $40. The pullback from $61 to $40 has created a genuine entry point in a stock with an $83M record backlog, $45M in fresh contract wins, insider buying, and the 200-DMA providing technical support. The key-person risk (Bloch, age 93) is real but the business has already transitioned operational leadership to McClelland. The precision timing franchise is deeply embedded and benefits from the same defense tailwinds as LASR, but with actual profitability, dramatically lower valuation risk, and a 0.31 beta that lets you sleep at night.
LASR is the more exciting story, and if directed energy production contracts materialize in 2028-2030, the stock could double or triple from here. But at $65.76, you’re paying for that outcome in advance with no margin of safety. The right move is to watch LASR for a pullback to $45-50 — which could come on any quarterly miss, defense budget headline, or HELSI setback — and build a position then.
Own both, but weight FEIM heavier right now (70/30 or 60/40). They have minimal overlap — FEIM is precision timing, LASR is directed energy lasers. Both serve the same customer (DoD) and benefit from the same tailwinds (defense modernization, counter-UAS, space proliferation), but through different technology stacks. The low correlation (FEIM beta 0.31 vs. LASR beta 2.34) means they provide genuine diversification within the defense-tech theme.
The ideal approach: buy FEIM now at ~$40, set a limit order for LASR at $45-50, and add LASR if/when it pulls back. If LASR never pulls back, you still have the less exciting but more reliable defense-tech exposure through FEIM.
FEIM: - Stock Analysis — FEIM (financials, balance sheet, cash flow, statistics) - Q3 FY2026 Earnings Release — March 11, 2026 - Craig-Hallum Initiation — Sep 2025 - Freedom Capital Downgrade — Dec 2025 - $45M Contract Awards — Mar 2026 - Insider Trades — MarketBeat
LASR: - Stock Analysis — LASR (financials, balance sheet, cash flow, statistics) - nLIGHT HELSI Phase 2 Contract ($171M) — Nov 2023 - nLIGHT $201M Equity Offering — Feb 2026 - nLIGHT CEO Insider Sales — Form 4 - Baird Initiation at $95 — Mar 2026 - LASR Deep-Dive — internal research — Mar 2026